Table 3.

Summary of Next-Line Therapy in the Overall Population and by Region

Category	Overall Population				Central/Eastern Europe				North America/Western Europe				Rest of World
	Tivozanib (n = 260)		Sorafenib (n = 257)		Tivozanib (n = 229)		Sorafenib (n = 228)		Tivozanib (n = 22)		Sorafenib (n = 18)		Tivozanib (n = 9)		Sorafenib (n = 11)
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
Patients who discontinued assigned therapy*	190	73†	226	88	165	72	198	87	16	73†	17	94	9	100	11	100
Patients with next-line therapy	68	26	168	65	52	23	145	64	13	59	14	78	3	33	9	82
Patients with next-line targeted therapy	34	13	162	63	26	11	139	61	7	32	14	78	1	11	9	82
VEGFR inhibitor	18	7	158	61	13	6	138	61	5	23	11	61	0		9	82
Tivozanib	0		156	61	0		138	61	0		10	56	0		8	73
mTOR inhibitor	16	6	4	2	13	6	1	< 1	2	9	3	17	1	11	0
Cytokines	14	5	3	1	14	6	3	1	0		0		0		0
Radiotherapy	10	4	2	1	4	2	2	1	5	23	0		1	11	0
Other	10	4	1	< 1	8	3	1	< 1	1	5	0		1	11	0

Abbreviations: mTOR, mammalian target of rapamycin; VEGFR, vascular endothelial growth factor receptor.

^*On or before August 27, 2012.

^†One patient erroneously appears as “discontinued” but was ongoing as of August 27, 2012.